KR20170138307A - Ultrasonic extract of Lespedeza cuneate and method for extracting the same - Google Patents
Ultrasonic extract of Lespedeza cuneate and method for extracting the same Download PDFInfo
- Publication number
- KR20170138307A KR20170138307A KR1020160070541A KR20160070541A KR20170138307A KR 20170138307 A KR20170138307 A KR 20170138307A KR 1020160070541 A KR1020160070541 A KR 1020160070541A KR 20160070541 A KR20160070541 A KR 20160070541A KR 20170138307 A KR20170138307 A KR 20170138307A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- present
- ultrasonic
- lipstick
- cancer
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 106
- 238000000034 method Methods 0.000 title claims abstract description 39
- 241000522169 Lespedeza Species 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 239000004480 active ingredient Substances 0.000 claims abstract description 28
- 235000013305 food Nutrition 0.000 claims abstract description 24
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 23
- 238000002604 ultrasonography Methods 0.000 claims abstract description 22
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 20
- 239000002537 cosmetic Substances 0.000 claims abstract description 18
- 239000006188 syrup Substances 0.000 claims abstract description 13
- 235000020357 syrup Nutrition 0.000 claims abstract description 13
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 114
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 19
- 235000013376 functional food Nutrition 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 17
- 230000036541 health Effects 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 239000006210 lotion Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- 235000009508 confectionery Nutrition 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 244000299461 Theobroma cacao Species 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 235000019219 chocolate Nutrition 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 235000012149 noodles Nutrition 0.000 claims description 5
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 235000015243 ice cream Nutrition 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 235000013550 pizza Nutrition 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 210000004709 eyebrow Anatomy 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 21
- 239000003814 drug Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000002137 ultrasound extraction Methods 0.000 abstract description 9
- 241001454694 Clupeiformes Species 0.000 abstract description 6
- 235000019513 anchovy Nutrition 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 34
- 206010061218 Inflammation Diseases 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 229930003935 flavonoid Natural products 0.000 description 13
- 150000002215 flavonoids Chemical class 0.000 description 13
- 235000017173 flavonoids Nutrition 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 108010057466 NF-kappa B Proteins 0.000 description 11
- 102000003945 NF-kappa B Human genes 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 102100021546 60S ribosomal protein L10 Human genes 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 9
- 102100021660 60S ribosomal protein L28 Human genes 0.000 description 8
- 230000002292 Radical scavenging effect Effects 0.000 description 8
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 7
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 230000000749 insecticidal effect Effects 0.000 description 5
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 3
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- -1 body cleanser Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000002481 ethanol extraction Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002525 ultrasonication Methods 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004611 cancer cell death Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000036996 cardiovascular health Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 244000297531 Lespedeza cuneata Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 244000141353 Prunus domestica Species 0.000 description 1
- 235000011435 Prunus domestica Nutrition 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 229940027779 persimmon extract Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/48—Ultrasonic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
Abstract
The present invention relates to an ultrasonic extract of an anchovy and an extract thereof, and more particularly, to an anchovy extract having antioxidant, anti-inflammatory and anticancer effects using an ultrasonic extraction method and a method for effectively producing the same. The method for preparing the non-squeezed ultrasound extract according to the present invention can effectively extract the active ingredient contained in the syrup by treating the ultrasound under specific conditions after adding the solvent to the syrup, Has excellent antioxidative, anti-inflammatory and anti-cancer activities. Therefore, the non-squeezable ultrasound extract prepared by the method of the present invention can be used for various industrial fields such as medicines, foods, cosmetics and the like with various functionalities. Particularly, since it is a natural medicinal plant and can be edible, the composition of the present invention containing an extract derived therefrom as an active ingredient has safety advantages even for long-term use.
Description
The present invention relates to an ultrasonic extract of an anchovy and an extract thereof, and more particularly, to an anchovy extract having antioxidant, anti-inflammatory and anticancer effects using an ultrasonic extraction method and a method for effectively producing the same.
It is a perennial herbaceous or supernatural herb that grows in mountains and fields around the country. The growing environment grows wherever it is sunny. The key is about 1m, the leaves are shifted, there is no hairs on the surface of the leaves, there are fine hairs on the back, the length of the leaves is 1 ~ 2㎝, and the width is 0.2 ~ 0.4㎝. The stalk is climbing thinly and has many fine hairs. The flower is shorter than the leaf, attached to the leaf axilla with a butterfly shape, and bloomed in white, with a purple stripe in the center. The fruit is dark brown and runs in October and contains one seed with red spots on the yellowish green background. Outposts containing roots are used for medicinal purposes. As a generic name, it is called "the main gate", and it has become more common to drink alcohol recently.
On the other hand, the flavonoid is derived from the flavus which means yellow in Greek, and refers to a plant pigment having flavone as a basic structure. Vitamin P (permeable vitamin) or vitamin C2 (vitamin C as a synergist) is also called. It is relatively small in animals, and is contained in many kinds of leaves, flowers, roots, fruits, and stems of plants. It also has antimicrobial, anticancer, antiviral, antiallergic and anti-inflammatory activity, and it is reported that there is little toxicity. In addition, as the fact that it inhibits in vivo oxidative action is known, there is a growing interest in the development and application of flavonoid-based materials.
The substances such as phenolic compounds, flavonoids and tocopherols of the syrup can inhibit the action of reactive oxygen species and prevent adult diseases such as cancer, cardiovascular diseases, and contribute to delay and prevention of aging. Many hydroxyl groups (-OH) present in polyphenols have the property of easily binding to various compounds and thus have excellent antioxidative, anti-cancer and anti-inflammatory effects, and flavonoids are known to have high antioxidant ability by effectively removing active oxygen species Like polyphenols, it is known to have antiviral, anti-inflammatory and anti-cancer effects. Therefore, there is a need for research on a method for efficiently producing such an insecticidal extract.
In general, the active ingredient in the syrup can be extracted using a solvent such as water or ethanol. When extracting with water, high-temperature and long-time extraction conditions are required, and the components contained in the syrup can be decomposed. It is disadvantageous in that an insecticidal extract having low physiological activity is obtained due to the evaporation phenomenon. On the other hand, in the case of ethanol extraction, it can be extracted by lowering the extraction temperature and the extraction time. However, since the organic solvent is used, the cost is increased and there is a problem such as environmental pollution.
The inventors of the present invention have found that when an ultrasonic treatment is carried out under a specific condition after adding ethanol to a non-syrup, the antioxidative, anti-inflammatory and anti-cancer The present inventors have completed the present invention by confirming that it is possible to produce an insecticidal extract having excellent activity.
Accordingly, it is an object of the present invention to provide a pharmaceutical composition which can prevent or treat diseases such as inflammation disease and cancer by using an aspirate ultrasonic extract.
It is another object of the present invention to provide a food composition capable of preventing or ameliorating diseases such as inflammation disease and cancer by using an aspirate ultrasonic extract.
It is still another object of the present invention to provide a health functional food which can prevent or ameliorate diseases such as inflammation disease and cancer by using an aspirate ultrasonic extract.
It is still another object of the present invention to provide a cosmetic composition which can improve skin through antioxidant or anti-inflammatory function using non-sour ultrasound extract.
It is still another object of the present invention to provide a method for producing an aqueous non-squeezable extract capable of effectively and rapidly extracting an active ingredient of an insecticide.
Yet another object of the present invention is to provide an ultrasonic extract prepared by the above method.
In order to achieve the above-mentioned object of the present invention,
There is provided a pharmaceutical composition for preventing or treating an inflammatory disease or cancer disease comprising an aspirate ultrasonic extract as an active ingredient.
In one embodiment of the present invention, the non-squeaky ultrasound extract may be an extract obtained by adding ethanol to a syrup followed by treatment with ultrasound.
In one embodiment of the present invention, the cancer may be colon cancer or lung cancer.
In addition, the present invention provides a food composition for preventing or ameliorating an inflammatory disease or cancer disease comprising an aspirate ultrasonic extract as an active ingredient.
The present invention also provides a health functional food for preventing or ameliorating an inflammatory disease or cancer disease comprising an aspirate ultrasonic extract as an active ingredient.
In one embodiment of the present invention, the food is selected from the group consisting of beverage, meat, chocolate, foods, confectionery, pizza, ram noodles, gums, candy, ice cream, alcoholic beverages, .
In addition, the present invention provides a cosmetic composition having antioxidant or anti-inflammatory activity comprising an aspirate ultrasonic extract as an active ingredient.
In one embodiment of the present invention, the cosmetic composition may be at least one selected from the group consisting of a soft lotion, a gel, a water-soluble liquid, a milk lotion, a nutritional cream, a massage cream, an essence, an oil in water emulsion, , Oil dispersions in aqueous phase using microspheres, ionic lipid vesicles, nonionic lipid vesicles, ointments, cleansing foams, cleansing waters, packs, body oils, oil-in-oil makeup bases, watershed makeup bases, foundations, skins And may be one type of formulation selected from the group consisting of a cover, a lipstick, a lip gloss, a face powder, a two-way cake, an eye shadow, a mascara, a cheek color and an eyebrow pencil.
Further, the present invention provides a method for producing a microcapsule comprising the steps of: a) treating ultrasonic waves after adding a solvent to a syringe; And b) centrifuging the solution after the step a), and filtering the separated supernatant.
In one embodiment of the present invention, the solvent may be ethanol.
In one embodiment of the present invention, the step (a) may be performed by immersing a syringe in an aqueous solution of 20 to 60 w / v% ethanol and treating the syringe at 20 to 30 ° C for 1 to 24 hours.
In one embodiment of the present invention, in the step b), the solution having been subjected to the step a) is centrifuged at a temperature of 0 to 10 ° C at a speed of 3000 to 5000 rpm for 5 to 30 minutes, Lt; RTI ID = 0.0 > 10 < / RTI >
In one embodiment of the present invention, after the step b), c) may further comprise pulverizing the filtered extract.
The In one embodiment, the frequency of the ultrasonic waves in the ultrasonic processing may be 20 to 30 kHz.
In addition, the present invention provides an ultrasonic extract obtained by the above method.
The method for preparing the non-squeezed ultrasound extract according to the present invention can effectively extract the active ingredient contained in the syrup by treating the ultrasound under specific conditions after adding the solvent to the syrup, Has excellent antioxidative, anti-inflammatory and anti-cancer activities. Therefore, the non-squeezable ultrasound extract prepared by the method of the present invention can be used for various industrial fields such as medicines, foods, cosmetics and the like with various functionalities. Particularly, since it is a natural medicinal plant and can be edible, the composition of the present invention containing an extract derived therefrom as an active ingredient has safety advantages even for long-term use.
FIG. 1 is a graph showing the results of measurement of the total flavonoid content of the anthracnose extract according to the extraction conditions.
FIG. 2 is a graph showing the DPPH radical scavenging activity of the extract of the anthilliae according to the extraction conditions (IQ: isoquercetin-treated group, R: treated group).
Fig. 3 is a graph showing the results of measurement of the inhibitory effect on the NO production of the extract of Asuncio according to the extraction conditions (P3: isoquercitrin-treated group).
FIG. 4 shows the results of measuring the inhibitory effect of NF-κB promoter binding activity on HUVEC cells with increased oxidative stress by TNF-α, respectively (P3: isoquercitrin-treated group) .
FIG. 5 relates to the results of principal components analysis of yield, antioxidant properties, anti-inflammatory activity, anti-arteriosclerosis activity, and anticancer activity according to the extraction conditions of anchovy.
The present invention provides a composition comprising an ashless ultrasonic extract as an active ingredient.
The composition of the present invention can be used for various purposes and applications requiring antioxidant, anti-inflammatory or anti-cancer activity. Specifically, the composition of the present invention can impart antioxidative activity to articles applied in various industrial fields such as medicines, cosmetics, It can be used as a functional material, and can also be used as a medicine preservative, a cosmetic preservative, a food preservative, a pharmaceutical additive, a cosmetic additive, a food additive, and a feed additive.
Hereinafter, the present invention has been described in detail in the form of medicines, foods, and cosmetics to which the composition of the present invention can be applied.
The composition of the present invention may be a pharmaceutical composition for the prevention or treatment of an inflammatory disease or cancer disease comprising an aspirate ultrasonic extract as an active ingredient.
The pharmaceutical composition of the present invention can be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, A lubricant or a flavoring agent can be used.
The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.
The pharmaceutical composition may be in the form of granules, powders, tablets, coated tablets, capsules, suppositories, liquids, syrups, juices, suspensions, emulsions, drops or injectable solutions. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
In one embodiment of the present invention, the non-sour ultrasound extract of the present invention may be contained in an amount of 0.00001 to 99% by weight based on the total weight of the composition.
In another embodiment of the present invention, the non-syringe ultrasonic extract of the present invention may be contained at a concentration of 0.1 to 1000 μg / ml on the composition.
Examples of the inflammation-related diseases in which the pharmaceutical composition of the present invention can exhibit a therapeutic effect include rhinitis, asthma, acute pain, chronic pain, periodontitis, gingivitis, inflammatory bowel disease, gout, myocardial infarction, arteriosclerosis, congestive heart failure, hypertension But are not limited to, angina pectoris, gastric ulcer, Alzheimer's disease, cerebral infarction, Down's syndrome, multiple sclerosis, obesity, diabetes, dementia, depression, schizophrenia, tuberculosis, sleep disorders, sepsis, burn or pancreatitis.
Examples of the cancer that can be treated by the pharmaceutical composition of the present invention include gastric cancer, liver cancer, colon cancer, lung cancer, breast cancer, uterine cancer, esophageal cancer, pancreatic cancer, skin cancer and blood cancer. .
The present invention also provides a method of preventing or treating an inflammatory or cancer-related disease, comprising the step of administering the pharmaceutical composition to a suspected individual of an inflammatory or cancer-related disease.
In the present invention, the suspected individual of the inflammatory or cancer-related diseases refers to all animals including humans who have developed or are capable of developing inflammation or cancer-related diseases. The pharmaceutical composition comprising the non- By administering to a suspected individual with an associated disease, the individual can be treated efficiently. Inflammation or cancer-related diseases are as described above.
The term "administering" as used herein means introducing the pharmaceutical composition of the present invention into a subject suspected of having an inflammatory or cancer-related disease by any appropriate method, and the administration route may be an oral or non- May be administered via various routes of administration.
The method of treatment of the present invention may comprise administering a pharmaceutically effective amount of a pharmaceutical composition comprising an insecticidal ultrasound extract.
The term " pharmaceutically effective amount " as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and the effective dose level will vary depending on the species and severity, age, The type of disease, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention may be administered as an individual therapeutic agent or in combination with another therapeutic agent, and may be administered sequentially or simultaneously with a conventional therapeutic agent. And can be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art. The preferred dosage of the composition of the present invention will depend on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration, and the period of time, and the appropriate total daily dose can be determined by treatment within the proper medical judgment.
The composition of the present invention may also be a food composition. The food composition may contain various flavors or natural carbohydrates as an additional component, such as an ordinary food composition, in addition to an active ingredient, an insecticidal ultrasound extract.
Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. The above-described flavors can be advantageously used as natural flavorings (tau martin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.).
The food composition of the present invention can be formulated in the same manner as the above pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolates, foods, confectionery, pizza, ram noodles, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, .
In addition, the above food composition may contain various additives such as various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring agents and intermediates such as cheese and chocolate, Acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the food composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks.
The non-squeezable ultrasound extract, which is an active ingredient of the present invention, is a substance extracted from a natural medicinal plant. Since it has almost no side effects such as chemicals, it can be safely used for long-term administration for antioxidant, anti-inflammation and anticancer functions.
The present invention may also be a health functional food for preventing or ameliorating an inflammatory disease or a cancerous disease comprising an aspirate ultrasonic extract as an active ingredient.
The health functional food of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, rings and the like for the purpose of preventing or improving inflammatory diseases or cancer diseases.
In the present invention, the term " health functional food " refers to a food prepared or processed using raw materials or ingredients having useful functions in accordance with the Act on Health Functional Foods, and the nutrients are controlled Physiological action, etc., for the purpose of obtaining a beneficial effect.
The health functional foods of the present invention may contain conventional food additives and, unless otherwise specified, whether or not they are suitable as food additives are classified according to the General Rules for Food Additives approved by the Food and Drug Administration, Standards and standards.
Examples of the items listed in the above-mentioned "food additives" include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as persimmon extract, licorice extract, crystalline cellulose, high color pigment and guar gum; L-glutamic acid sodium preparations, noodle-added alkalis, preservative preparations, tar coloring preparations and the like.
For example, the health functional food in the form of tablets may be prepared by granulating a mixture obtained by mixing the active ingredient of the present invention with an excipient, a binder, a disintegrant and other additives, granulating the mixture in a conventional manner, The mixture can be directly compression molded. In addition, the health functional food of the tablet form may contain a mating agent or the like if necessary.
The hard capsule of the capsule form of the health functional food may be prepared by filling a normal hard capsule with a mixture of the non-sour lysozyme extract as an active ingredient of the present invention with an additive such as an excipient and the soft capsule may contain the above extract as an excipient And mixing the mixture with an additive into a capsule base such as gelatin. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a coloring agent, a preservative and the like, if necessary.
The ring-shaped health functional food can be prepared by molding a mixture of an active ingredient of the present invention and an excipient, a binder, a disintegrant, and the like in accordance with a conventionally known method, and if necessary, Or it may be coated with a material such as starch, talc.
The granular health functional food may be prepared by granulating a mixture of an active ingredient of the present invention and an excipient, a binder, a disintegrant, and the like in a granular form by a conventionally known method, and if necessary, adding a flavoring agent, And the like.
As shown in the following examples, the health functional food containing the non-squeezable ultrasound extract of the present invention as an active ingredient has been experimentally proved to have excellent antioxidative, anti-inflammatory and anti-cancer effects and is effective in preventing or ameliorating inflammation-related diseases and cancer.
The health functional food may be a beverage, a meat, a chocolate, a food, a confectionery, a pizza, a ramen, a noodle, a gum, a candy, an ice cream, an alcoholic beverage, a vitamin complex and a health supplement food.
In addition, the composition of the present invention may be a cosmetic composition in addition to a pharmaceutical composition or a food composition.
Since the non-sour ultrasound extract of the present invention is excellent in antioxidative and anti-inflammatory activities, the composition comprising the non-sour organic extract as an active ingredient is useful as an effective ingredient for preventing damage to human cells and promoting aging, Skin protection and skin treatment, so that it can be effectively used as a cosmetic composition.
When the composition of the present invention is prepared with a cosmetic composition, the composition of the present invention may contain not only the above-mentioned non-aqueous ultrasonic extract but also components commonly used in cosmetic compositions, such as antioxidants, stabilizers, , Customary adjuvants such as pigments and flavoring agents, and carriers.
In addition, the composition of the present invention may be mixed with an antioxidant that has been used in the past so long as it does not impair the skin protecting effect by reacting with the non-sour ultrasound extract, in addition to the above-described non-sour ultrasound extract.
Examples of products to which the cosmetic composition of the present invention can be added include cosmetics such as astringent lotion, softening longevity lotion, nutrition lotion, various creams, essences, packs, foundation and the like, cleansing, cleanser, soap, , And shampoo.
As a specific formulation of the cosmetic composition of the present invention, there may be mentioned a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, It includes formulations such as soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, latex, lipstick, makeup base, foundation, press powder, loose powder, eye shadow.
The present invention relates to a method for producing a microcapsule comprising the steps of: a) treating ultrasonics after addition of a solvent to a syringe; And b) centrifuging the solution obtained in the step a), and filtering the separated supernatant, characterized in that it provides a method for producing an ultrasonic extract.
The step (a) of the present invention is a step of adding ultrasonic waves after adding the solvent to the syringe.
The solvent may be any pharmaceutically acceptable organic solvent, and water or an organic solvent may be used. Examples of the solvent include, but are not limited to, purified water, methanol, ethanol, Alcohol having 1 to 4 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate (including ethyl acetate) containing propanol, isopropanol, butanol, ), Methylene chloride, hexane, and cyclohexane may be used alone or in combination. It is preferable to use ethanol (alcohol), more preferably 20 to 60 w / v% ethanol.
In one embodiment of the present invention, the step a) may be a step of immersing a syringe in an aqueous solution of 20 to 60 w / v% ethanol and treating the ultrasonic wave at 20 to 30 ° C for 1 to 24 hours.
In another embodiment of the present invention, the frequency of the ultrasonic wave in the ultrasonic processing may be 20 to 30 kHz.
In the step b) of the present invention, the solution having been subjected to the step a) is centrifuged and the separated supernatant is filtered. Specifically, the solution having been subjected to the step a) is filtered at a temperature of 0 to 10 ° C at a rate of 3000 to 5000 rpm For 5 to 30 minutes, and filtering the separated supernatant through a membrane having a pore size of 0.2 to 10 mu m.
The method for producing the non-squeezed ultrasonic extract of the present invention may further include the step of c) pulverizing the filtered extract after the step b).
That is, the primary extract extracted through the step b) of the present invention can be prepared into a powder state by an additional process such as vacuum distillation, freeze-drying, or spray drying. Further, the primary extract can be further purified by using various chromatographies such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography and the like, You can get it.
Therefore, in the present invention, the non-squeezing ultrasonic wave extract is a concept including all the extracts, fractions and tablets obtained in each step of extraction, fractionation or purification through the steps a), b) and c), diluted solution thereof, to be.
In addition, the present invention provides a non-squeezable ultrasound extract prepared by the above-described method.
The extract of the present invention is more effective in extracting the extract than the extract obtained by using ethanol alone, and further exhibiting excellent antioxidative, anti-inflammatory and anti-cancer activities.
Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are for further illustrating the present invention, and the scope of the present invention is not limited to these examples.
< Example 1>
Preparation of an Asiatic Extract
≪ 1-1 > Preparation of Unsulfurized Powder
The bisuri (nomenclature used in this experiment: Lespedeza cuneata , domestic) were directly sampled and dried. All samples were milled to 0.6 mm size with a pin mill and stored frozen.
<1-2> Preparation of Anthracnose Extract Using Ethanol Solvent Extraction
Ethanol (60%) of 100 times (w / v) was added to the non-syrupy dry powder prepared in Example <1-1>, and the mixture was stirred at 25 ° C for 24 hours for extraction. The thus-prepared 'non-sour ethanol extract' was used as a comparative control sample in the following experiment.
<1-3> Preparation of anisakii extract using ultrasonic extraction
The ultrasonic extraction method used in the present invention was to extract ultrasonic waves by generating ultrasonic waves at 28 kHz and
The dried non-syrupy powder prepared in Example <1-1> was immersed in an aqueous solution of 0, 20, 40 and 60 w / v% ethanol, and the extraction time was 1, 2, 3 , 6, 9, 12 and 24 hours, respectively. The extract was centrifuged (4000 rpm, 20 minutes) at 4 ° C, and the separated supernatant was filtered through a 0.22 μm-pore membrane and then concentrated under reduced pressure (Evaporator, Tokyo rikakikai co.Ltd., Japan) Was used as an analytical sample in the following experiment.
≪ 1-4 > Extraction Yield of Anthracnose Extract ( % )
The extraction yields (%) of each of the non-sour extracts prepared in Examples 1-2 and 1-3 were determined after the lyophilization (weight of the dried extract) / (raw material weight ) × 100. As a result, as shown in Table 1, extraction yield of 13.5% was found in the
(° C)
(hr)
(w / v%)
(%)
< Experimental Example 1>
The total flavonoid content
In this experiment, the content of total flavonoids contained in each of the non-sour extracts prepared in Examples <1-2> and <1-3> was measured.
The total flavonoid content was determined according to the Folin-Denis method (Swain T & Hills WE 1959, J Sci Food Agric 10: 63-68). The phenolic constituents of Prunus domestica I-the quantitative analysis of phenolic constituents.
Briefly, 0.1 mL of Folin-Ciocalteu's phenol reagent and 1.4 mL of distilled water were added to 0.2 mL of the sample, followed by the addition of 0.3 mL of 20% sodium carbonate, followed by 20 min of incubation in a dark place. Then, the absorbance was measured at 765 nm using a microplate spectrophotometer , Bioteck, VT, USA) were measured. As a standard substance, the content was indicated by using a routine.
As a result, as shown in Fig. 1 and Table 2, L2 (202.36 uM routine / 2 mg), L3 (232.7 uM routine / 2 mg), L6 (198.83 uM routine / 2 mg), L8 (248.5 uM routine / 2 mg), L10 (203.58 uM routine / 2 mg), and L24 (262.4 uM routine / 2 mg). On the other hand, L8 and L24 showed the highest total flavonoid contents under ultrasonic extraction conditions (p <0.05). The optimum extraction conditions of total flavonoid extracts were 60% ethanol solvent, 60% solvent extraction method than ultrasonic extraction method.
(° C)
(hr)
(w / v%)
(%)
< Experimental Example 2>
Of the extract DPPH Radical scavenging activity
In this experiment, DPPH radical scavenging activity was examined to evaluate the antioxidative activity of each of the non-sour extracts prepared in Examples <1-2> and <1-3>.
Methods for measuring DPPH radical scavenging activity are described in Llorach et al. (2002) method. Briefly, the reducing power of each sample against the DPPH (2,2-diphenyl-1-picrylhydrazyl) radical was measured. The DPPH solution was made up to 10 μM using 80% methanol. The absorbance was measured at 517 nm using a spectrophotometer (Agilent 8453, Agilent Technologies, CA, USA) after reacting 0.1 ml of the sample and 2.9 ml of the DPPH solution. Ascorbic acid was used as a standard for the comparison of the activity of the sample. In the control blank, 0.1 mL of 50% methanol was added instead of the sample. The sample blank was measured by adding 2.9 mL of 50% methanol instead of the DPPH solution.
DPPH radical scavenging activity (%) = (Abs Blank- Abs Sample / Abs Blank ) 100
As a result, as shown in Fig. 2 and Table 3, L0 using the
(° C)
(hr)
(w / v%)
(%)
< Experimental Example 3>
The inhibitory effect on the production of NO (nitrogen monoxide) by the extract condition
In this experiment, the inhibitory effect of NO (nitrogen monoxide) formation on the anti-inflammatory activity of each of the non-sour extracts prepared in Examples <1-2> and <1-3> was investigated.
<3-1> Cell culture
Mouse macrophage Raw 264.7 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS), 100 U / mL penicillin, 100 mg / mL streptomycin and Human Endothelial Growth Medium at 37 ° C in a 5% CO2 incubator . Cells were subcultured at 2-day intervals to maintain 70-80% confluency.
≪ 3-2 >
Raw 264.7 cells were adjusted to a cell number of 2 × 10 7 cells / mL using 10% FBS DMEM medium and cultured in a 96-well plate. After 24 hours, the samples were treated for 1 hour before, and then cultured for another 24 hours in a medium containing LPS (1 μg / mL) and samples. The amount of NO produced was measured using the Griess reaction. 50 μl of the cell culture supernatant was mixed with 50 μl of Griess reagent [1% (w / v) sulfanilamide, 0.1% (w / v) naphtylethylenediamine in 2.5% (v / v) phosphoric acid] The absorbance was measured at 540 nm using a microplate reader and quantified as the value for the standard concentration curve obtained by stepwise dilution of sodium nitrite (NaNO 2 ).
For reference, NO (nitrogen monoxide) is produced from L-arginine by NOS. When LPS (lipopolysaccharide), a cell wall component of gram-negative bacteria, binds to TLR (Toll like receptor) 4 of macrophages, it activates NF-κB transcription factor Thereby promoting protein expression of iNOS and eventually producing excess NO. It is known that NO produced is an active oxygen, which is involved in cytotoxicity and tissue damage, and plays an important role in inflammation induction. Therefore, a material inhibiting NO production may be useful as an anti-inflammatory functional material.
As a result, as shown in Fig. 3 and the following Table 4, the NO production amount was decreased in the extract of all conditions, as compared with the LPS group not containing the extract. In addition, extracts with similar inhibitory effect on NO formation were confirmed as compared with those treated with 20 μM of isoquercitrin, which is one of the representative functional materials contained in the non-sourdough. The highest inhibitory activity of L28 (24 h, 60% ethanol, ultrasonication) was found to be about 61% inhibitory.
(° C)
(hr)
(w / v%)
< Experimental Example 4>
Of the extract TNF by -α NF - κB Promoter binding inhibitory activity
In order to screen for the cardiovascular health-controlling efficacy of each of the non-sour extracts prepared in Examples <1-2> and <1-3> in this experiment, blood vessels of endothelial cells with increased oxidative stress by TNF- Was treated with an extract of Asisaceae having different extraction conditions to determine the inhibitory effect of NF-κB promoter binding activity.
Recently, interest in the inflammatory response in the blood vessels has been increasing as a cause of vascular disease. Inflammation is one of the in-vivo responses to various infectious agents such as external stimuli including tissue damage, and various immune cells undergo organic interactions. The induction of arteriosclerosis is caused by repeated physical or chemical stimulation of various risk factors and damage of vascular endothelial cells due to biological damage, and it is recognized that oxidative stress and inflammation play an important role in endothelial cell damage. Activated macrophages activate various nuclear cytokines and reactive oxygen species, activating nuclear factor-κB (NF-κB), which is a transcription factor of inflammatory response. As a result, inducible nitric oxide synthase (iNOS), cyclooxygenase- 2), resulting in inflammation. If this inflammatory reaction occurs continuously or excessively in the blood vessel, the initial response of atherosclerosis is activated.
Therefore, in this experiment, it was evaluated whether or not the extract of the present invention had cardiovascular health controlling effect through the inhibitory effect of NF-κB, which is a transcription factor of inflammatory reaction.
<4-1> Transformation and DNA extraction
MMP-1 plasmid DNA was incubated in competent cells at 42 ° C for 1 min. The reaction mixture was added to 0.4 ml of LB medium and incubated at 37 ° C for 1 hr with shaking at 250 rpm. The culture medium shaken in LB medium (
<4-2> Transfection
293T cells were transfected with NF-κB-luciferase viral vector to obtain viral particles. 293T cells were plated in a 10 cm dish at 7 × 10 5 cells / plate and cultured for 24 hours. After 24 hours of incubation, the cells were exchanged for antibiotic-free serum free medium for transfection, and 3 μg of each of MMP-1 plasmid DNA, psPAX2 and pMD2G DNA, 100 μl of Opti MEM mixed solution, 20 μl of lipofectamine and 100 μl of Opti MEM were prepared Respectively. The prepared DNA mixture and transfection reagent were mixed, vortexed, reacted at room temperature for 5 minutes, mixed with DNA-reagent mixture, and incubated for 24 hours.
<4-3> Infection
Human Umbilical Vein Endothelial Cell (HUVEC) was prepared to be 60% confluent. 5 mL of fresh medium and 5 mL of transfected cell medium were mixed and then filtered with 0.45 μM membrane filter. The prepared cell medium was removed, and the filtered medium containing 1 μl / mL of polybrene was added thereto, followed by incubation for 24 hours. Subsequently, selection was carried out until the uninfected cells were 100% killed by exchanging puromycin with 1 μg / mL of medium in control and infected cells. Nuclear factor-kappa B (NF-κB) luciferase-expressing HUVEC cell line was constructed by culturing the selected medium.
<4-4> Cardiovascular Health Regulation Screening
NF-κB luc-expressing HUVEC cells were counted in 96-well plates at 2 × 10 4 cells / mL and cultured in a 5% CO 2 , 37 ° C cell incubator for 24 hours. The cells were cultured for 24 hours in serum free medium. After 24 hours, the sample was treated with 100 μg / mL of Tumor Necrosis Factor-αlpha (TNF-α) for 1 hour. After 3 hours, the medium was removed and the cells were lysed with 100 μl of lysis buffer for 1 hour. 50 μl of luciferase reagent was added to 50 μl of the solution and measured using Spectramax (Molecular devices, Silicon Valley, CA, United States).
As a result, as shown in FIG. 4 and Table 5, when treated at a concentration of 100 μg / mL for each extraction condition, 64.8% in L0 (24 hours, 60% in ethanol, shaking), L20 (9 hours, 60% Ultrasound) showed the highest inhibitory effect (68.9%) and ultrasound was suppressed to similar level in shorter time. P3, which is isoquercitrin, was inhibited to 37.5%.
(° C)
(hr)
(w / v%)
< Experimental Example 5>
Anticancer efficacy of the extract of Asahiri extract according to extraction condition
In order to investigate the anticancer effects of each of the non-sour extracts prepared in Examples 1-2 and 1-3, human colon cancer cell lines and lung cancer cell lines were cultured in the same manner as in Example 1, After the treatment of the extracts, the degree of cancer cell death was measured.
In detail, human colon cancer cells (HT29, HCT116) and lung cancer cells (HCC827, HCC827 GR) were allowed to have a concentration of 4 x 10 4 cells / mL and then cultured in a 96-well plate for 24 hours. The extracts were then treated at a concentration of 100 μg / mL and then cultured for another 24 hours. MTS ([3- (4,5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2- ) -2H-tetrazolium) and phenazine methosulfate (PMS) were added and the absorbance at 492 nm and 690 nm was measured after 1 hour. The killing effect of the extract on cancer cells was relative to 100% of the untreated group after subtracting the absorbance at 690 nm from the absorbance at 492 nm.
As a result, as shown in Table 6, it was confirmed that the extract of the present invention had an anticancer effect on lung cancer cells and colon cancer cells. In particular, the anticancer activity of L2, L6 and L10 was excellent overall, and the anticancer activity against HCC 827 cell which is a lung cancer cell line was compared with that of corn ethanol extract prepared by the conventional ethanol extraction method for 3 hours or 12 hours by ultrasonication (L9, L10, L11, L21, L22, and L23), and L14 (6 hours,
(° C)
(hr)
(w / v%)
< Experimental Example 6>
Analysis of Principal Component of Extracts by Extraction Conditions
(DPPH), total flavonoid content (TF), anti-inflammatory (AI), anti-photoaging (AP), anti-aging activity The results of principal component analysis (PCA) of anti-atherosclerosis (AA), anticancer activity (HCC827; H8, HCC827GR; H8G, HCT116; HCT116; 116, HT29; 29) .
As a result, the first principal component (PC1) and the second principal component (PC2) accounted for 34.93% and 16.19%, respectively, accounting for 51.12% of the total variation. In the ultrasonic extraction condition, the samples located in the negative direction of the first main component were mainly 3 hours, 9 hours, 12 hours and 24 hours, and the solvent concentrations were 20%, 40% and 60% ethanol extracts. It was confirmed that the yield and anticancer activity of L10 (ultrasound-3 hours-20% EtOH) and L27 (ultrasonic-24 hours -40% EtOH) L3 (ultrasound-1 hour-60% EtOH), L16 (ultrasound-6 hours), and 60% ethanol extracts were used for the samples located in the negative direction of the second main component. -60%). The antioxidant properties and anti-arteriosclerotic activity of the extracts were found to be high.
The present invention has been described with reference to the preferred embodiments. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (15)
Wherein the non-squeezed ultrasound extract is an extract obtained by adding ethanol to a syrup followed by treatment with ultrasound.
Wherein said cancer is colon cancer or lung cancer.
Wherein the food is selected from the group consisting of beverage, meat, chocolates, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, Health functional food for prevention or improvement of disease.
The cosmetic composition may be an oil in an aqueous phase using a softening lotion, a gel, a water-soluble liquid, a milk lotion, a nutritional cream, a massage cream, an essence, an oil in water emulsion, a water in oil emulsion, a facer anhydrous product, Lipid, lip gloss, face powder, lipstick, lipstick, lipstick, lipstick, lipstick, lipstick, lipstick, lipstick, lipstick, lipstick, Wherein the cosmetic composition is one kind of a formulation selected from the group consisting of two-way cakes, eye shadow, mascara, cheek color, and eyebrow pencil.
b) centrifuging the solution after step a), and filtering the separated supernatant.
Wherein the solvent is ethanol.
Wherein the step (a) comprises immersing the syrup in an aqueous solution of 20 to 60 w / v% ethanol, and treating the syringe for 1 to 24 hours at 20 to 30 ° C.
In the step b), the solution having been subjected to the step a) is centrifuged at a temperature of 0 to 10 ° C at a speed of 3000 to 5000 rpm for 5 to 30 minutes, and the separated supernatant is filtered with a membrane having a pore size of 0.2 to 10 μm ≪ / RTI >
Further comprising the step of: c) after the step b), pulverizing the filtered extract.
Wherein the frequency of the ultrasonic waves in the ultrasonic treatment is 20 to 30 kHz.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160070541A KR20170138307A (en) | 2016-06-07 | 2016-06-07 | Ultrasonic extract of Lespedeza cuneate and method for extracting the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160070541A KR20170138307A (en) | 2016-06-07 | 2016-06-07 | Ultrasonic extract of Lespedeza cuneate and method for extracting the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170181559A Division KR101911003B1 (en) | 2017-12-27 | 2017-12-27 | Ultrasonic extract of Lespedeza cuneate and method for extracting the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170138307A true KR20170138307A (en) | 2017-12-15 |
Family
ID=60954562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160070541A KR20170138307A (en) | 2016-06-07 | 2016-06-07 | Ultrasonic extract of Lespedeza cuneate and method for extracting the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20170138307A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190086132A (en) * | 2018-01-12 | 2019-07-22 | 중앙대학교 산학협력단 | A pharmaceutical composition comprising fraction of Lespedeza cuneata extract for preventing or treating cancer |
| KR102628614B1 (en) | 2023-03-09 | 2024-01-25 | (주)한국아이지에이 | Unmanned Checkout Counter of RFID |
-
2016
- 2016-06-07 KR KR1020160070541A patent/KR20170138307A/en active Search and Examination
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190086132A (en) * | 2018-01-12 | 2019-07-22 | 중앙대학교 산학협력단 | A pharmaceutical composition comprising fraction of Lespedeza cuneata extract for preventing or treating cancer |
| KR102628614B1 (en) | 2023-03-09 | 2024-01-25 | (주)한국아이지에이 | Unmanned Checkout Counter of RFID |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230075384A1 (en) | Composition containing plant extracts | |
| KR102166279B1 (en) | Composition for Anti-Oxidant, Anti-Bacterial and Anti-Inflammatory Effect Comprising Plant Complex Extracts as Active Ingredient | |
| KR101295368B1 (en) | Composition for skin wrinkle improvement comprising extracts of honeybush extract or its fermentation solution as an active ingredient | |
| KR102065185B1 (en) | Composition for Improving Skin Conditions with Improved Anti-Bacterial, Anti-inflammatory, Anti-wrinkling, and Skin Whitening Property | |
| KR101806783B1 (en) | Ultrasonic extract of Arctium lappa and method for extracting the same | |
| KR20170138307A (en) | Ultrasonic extract of Lespedeza cuneate and method for extracting the same | |
| KR101911003B1 (en) | Ultrasonic extract of Lespedeza cuneate and method for extracting the same | |
| KR101188682B1 (en) | Composition for skin whitening comprising extracts of Veronica longiofolia L. | |
| KR101197101B1 (en) | Composition for skin whitening comprising extracts of Microalgae culture medium as an active ingredient | |
| KR102158134B1 (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
| KR101692889B1 (en) | Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases | |
| KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
| KR102248059B1 (en) | Composition for anti-inflammatory or whitening comprising green barley extract or its fractions and uses thereof | |
| KR102283946B1 (en) | Anti-inflammation Compound derived from Yuja and Isolating Method Thereof | |
| KR20070113330A (en) | A composition containing ecklonia stolonifera extract for skin external application | |
| KR101579500B1 (en) | Skin whitening composition comprising an extract obtained from roots of coix lachryma-jobi var. mayuen | |
| KR20130136753A (en) | Cosmetic composition comprising cercis chinensis or reynoutria japonica for. elata extract for skin whitening | |
| KR101514284B1 (en) | The pharmaceutical composition for prevention or treatment of cancer comprising an extract of Oplopanax elatus | |
| KR20130054518A (en) | Food composition comprising algae extracts and the use thereof | |
| KR101786802B1 (en) | Ultrasonic extract of Zea mays and method for extracting the same | |
| KR101971986B1 (en) | Composition comprising Silverberry like taxillus extract for preventing or treating cancer | |
| JP7028803B2 (en) | Whitening agent | |
| KR20170091391A (en) | A composition having anti-oxidation, anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
| KR20100042086A (en) | Composition for whitening containing extract of cortex cinnamomi cassiae | |
| KR101797843B1 (en) | A composition having anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment |